Clinical Research
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 7, 2006; 12(21): 3386-3392
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3386
Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders
Tryggve Ljung, Sofie Lundberg, Mark Varsanyi, Catharina Johansson, Peter T Schmidt, Max Herulf, Jon O Lundberg, Per M Hellström
Tryggve Ljung, Sofie Lundberg, Mark Varsanyi, Catharina Johansson, Per M Hellström, Peter Thelin Schmidt, Department of Gastroenterology and Hepatology, Karolinska University Hospital, Site Solna, Stockholm, Sweden
Max Herulf, Jon O Lundberg, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Supported by the Swedish Research Council, Novo Nordisk and the Bengt Ihre fund
Correspondence to: Tryggve Ljung, MD, PhD, Department of Gastroenterology and Hepatology, Karolinska University Hospital, Site Solna, SE-171 76 Stockholm, Sweden. tryggve.ljung@hotmail.com
Telephone: +46-8-51773877 Fax: +46-8-51772058
Received: October 12, 2005
Revised: October 28, 2005
Accepted: November 10, 2005
Published online: June 7, 2006
Core Tip